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Malignant pleural effusionsAbstract Background: 42–77% of exudative pleural effusions are due to malignant diseases
(Marel et al., 1993) [1]. This study aimed to evaluate the value of biochemical parameters of the
pleural aspirate in predicting success of chemical pleurodesis in adult patients with malignant
pleural effusion.
Patients and methods: This prospective study included 30 adult patients with malignant pleural
effusion diagnosed by clinical examination, Chest CT scanning and closed pleurocentesis. Patient
ages were mean of 60.4 ± 7.8 years, multiple sessions of closed pleurocentesis were carried out
followed by insertion of an intercostal tube. The pleural aspirate was then sent for chemical analysis
to detect Glucose, pH, and LDH. Pleurodesis was then done either by using Tetracycline (group A),
or Bleomycin (group B). All patients were then followed up for success of the pleurodesis process
within one month.
Results: Within one month of follow-up, rates of clinical response to treatment in group A
(Tetracycline) were successful in 40%; versus group B (73.3%). Complete response (CR) occurred
in group A cases (20%); versus 33.3% in group B; whereas partial response (PR) occurred in 3
cases of group A; versus 6 cases of group B; and treatment failure (TF) occurred in 9 of group
A cases versus 4 of group B cases. None of our patients died. Morbidity occurred in the form of
mild-to-moderate.
The success of the pleurodesis was closely-associated with higher glucose and pH levels together
with a low LDH level in the pleural ﬂuid.
Conclusion: The success of pleurodesis is usually higher when the pleural ﬂuid pH and glucose
levels are high & the LDH level is low in MPE.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Introduction
The visceral pleura (enveloping the entire surface of the lungs),
and the parietal pleura (covering the inner surface of the chest
154 S. Alsayed et al.wall, mediastinum and diaphragm); are deﬁcient only at the
hilum where the bronchi, pulmonary vessels and nerves enter
the lung substance [2].
Although normally, 0.1–0.2 mls/kg/body weight of a
plasma ultraﬁltrate exist as a thin layer of ﬂuid between the
parietal and visceral pleural layers, the rate of turn-over of
pleural ﬂuid in humans is rapid and may exceed 1 L/day.
And the volume of ﬂuid normally present in the pleural space
is small (of the order of 5–15 ml) [3,4].
Pleurodesis, from the Greek pleura and desis (binding
together) is intended to achieve a symphysis between parietal
and visceral pleura [5]. The most common indication for this
procedure is MPEs; less common are pneumothorax and recur-
rent benign pleural effusions. The methods of pleurodesis
include intrapleural instillation of a sclerosant agent, surgical
abrasion with a dry gauze sponge and videothoracoscopy.
The instillation of sclerosant agent is performed through a con-
ventional large-bore or a more comfortable small – bore chest
tube and recently through videothoracoscopy [6–12]. The
mechanism of pleurodesis is based on pleural irritation in order
to create an inﬂammatory reaction leading to ﬁbinogenesis [12].
The cellular and molecular mechanisms involved in pleurodesis
include the activation of the coagulation cascade of the pleura;
ﬁbrin deposition; ﬁbroblast recruitment, activation and prolif-
eration; and collagen deposition [6,14].
About 25% of effusions do not require therapy; the effu-
sions are small and stable. MPEs caused by lymphomas,
breast cancer, small cell lung cancer, or ovarian cancer may
respond to systemic chemotherapy or hormonal therapy.
Repeated percutaneous draining of effusions may lead to
tumour growth along the needle track and through the chest
wall. Patients who have received extensive prior systemic
therapy and those with chemotherapy-resistant tumours, like
non-small cell lung cancer, are not likely to respond to
systemic therapy [12–15].
Palliative approaches to the management of malignant
pleural effusions are necessary in such patients [16]. Patients
with symptomatic MPEs whose underlying cancer is unlikely
to respond to systemic treatment should have their pleural
ﬂuid drained. Patients with relatively large (>1000 ml) recur-
rent effusions whose symptoms resolve with drainage and
whose lung can fully expand are candidates for palliation.
Two general approaches to the palliative management of
symptomatic pleural effusions are chest tube drainage with
instillation of a sclerosing agent and thoracoscopic drainage
of the pleural effusion under local or general anaesthesia with
intraoperative sclerosis of the pleural space [15,17].
Aim of Work: The aim of the present study was to
evaluate the role of assessing the predictive value of certain
biochemical parameters (present in the pleural aspirate) in
assessment of the adequacy and efﬁciency of two pleurode-
sing agents namely Tetracyclin and Bleomycin which were
injected intrapleurally via conventional tube thoracostomy.
Patients and methods
Patient groups
Patient groups included 30 adult patients aged between 45 and
72 years (mean of 60.4 ± 7.8 years). There were 25 smokers
(83.3%), and 22 (73.3%) lived within industrial areas. Allpatients presented with malignant pleural effusion due to
different types of thoracic malignancies that were diagnosed
by clinical examination and special investigations (Chest CT
scanning and closed pleurocentesis). Patients were categorized
into two groups:
(A) Tetracyclin group: (15 patients).
(B) Bleomycin group: (15 patients).
Inclusion criteria
Presence of MPEs with: (1) Dyspnoea that improved after
large-volume thoracocentesis with subsequent recurrence of a
symptomatic pleural effusion. (2) No radiographic evidence
of conditions that might prevent lung re-expansion (i.e.
visceral pleural entrapment or atelectasis as a result of
bronchial occlusion). (3) Pleural ﬂuid cytologic studies or
pleural biopsies that are +ve for malignant cells. (4) No
endobronchial obstruction; acceptable patient performance
status and life expectancy.Exclusion criteria
Presence of MPEs with: (1) Inability to lie in the lateral decu-
bitus position. (2) Previously attempted, ipsilateral pleurodesis.
(3) Any change in the chemotherapy regimen within 4 weeks
before the patient entered the study (4) radiation therapy
2 weeks before referral for pleurodesis.Methodology
Preoperative preparation and patient evaluation
A thorough clinical examination including the patient’s his-
tory was carried out. Preoperative investigations included
plain chest X-rays in different positions, CT of the thorax,
in addition to the routine lab tests (full blood picture, blood
coagulation, renal and hepatic function tests). In all patients,
multiple sessions of closed pleurocentesis were carried out
and the pleural aspirate was then sent for chemical analysis.
This was followed by insertion of a 28-FG intercostal tube
under local anaesthesia in the 6th IC space connected to
underwater seal system. When the drainage of the intercostal
tube reached 6150 ml/day, pleurodesis was then done either
by using Tetracycline (group A = 15 patients), or Bleomycin
(group B = 15 patients). All patients were then followed up
over one month for success of the pleurodesis process which
was declared by clinical, and radiological measures, and
when the amount of daily pleural drainage dropped down
to 150 ml or less.Doses
In all patients, intrapleural injection of 10–15 ml 1% lidocaine
was done before the instillation of either: (A) tetracyclin as a
suspension of 20 mg/kg of tetracycline powder obtained from
tetracyclin capsule (maximum of 2 g) in 50 ml of normal saline
administered through the tube [18] or (2) Bleomycin as 60 mg
(minimum) or 150 mg (maximum) per instillation.
Figure 1 Incidence of clinical success between tetracycline and
bleomycin groups.
Figure 2 Mean glucose levels (mg/dl) between tetracycline and
bleomycin groups.
Figure 3 Mean pH between tetracycline and bleomycin groups.
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Complete response (CR)
No reaccumulation of ﬂuid within the ﬁrst 30 days as deter-
mined by clinical examination & chest X-ray.
Partial response (PR)
Symptomatic, minimal ﬂuid recurrence, not requiring aspira-
tion within the initial 30-day evaluation period.
Treatment failures (TF)
Reaccumulation of pleural ﬂuid necessitating re-aspiration of
ﬂuid in less than 30 days.
The chest tube was than clamped and patients were
repositioned every 15 min for 2 h to ensure a uniform dis-
persion of the agents. After 24 h, the tube was connected
to 15-cm water suction. It was removed when drainage
was <50 ml/8 h and chest X-ray ﬁlm indicated full expan-
sion of the lungs.Special investigations
Determination of pleural ﬂuid pH
The pleural ﬂuid obtained via aspiration by closed thoracocen-
tesis was sent for chemical analysis. One of the parameters
measured was the pH which had a role in predicting success
of pleurodesis. Pleural ﬂuid was collected for pH determina-
tion in a manner analogous to that for arterial blood gases.
All samples were collected anaerobically in a syringe rinsed
with 0.2 ml of heparin (1:1000) and quickly analysed within
30 min of collection. Pleural ﬂuid pH is stable for at least 2 h
using this technique and the reproducibility is +0.01 pH units
[22]. The pleural ﬂuid total protein, LDH and glucose concen-
trations were determined by standard autoanalyzer techniques
[23,24].
Statistical analysis
Data were statistically described in terms of mean ± standard
deviation (±SD), or frequencies (number of cases) and per-
centages when appropriate. Comparison of numerical vari-
ables between the study groups was done using Student’s t
test for independent samples in comparison with normally dis-
tributed data and Mann Whitney U test for independent sam-
ples when data were not normally distributed. For comparing
categorical data, Chi square (v2) test was performed. Exact test
was used instead when the expected frequency was less than 5.
p values less than 0.05 were considered statistically signiﬁcant.
All statistical calculations were done using computer program
SPSS (Statistical Package for the Social Science; SPSS Inc.,
Chicago, IL, USA) version 15 for Microsoft Windows.
Results
The causes of malignant effusion were matched well in the two
groups: metastatic adenocarcinoma and equally mesothelioma
in 5 cases (33.3%); metastatic squamous cell carcinoma and
lymphoma in 2 cases (13.3%); and one case of malignant lym-
phoma (6.6%) (Table 1).
Within one month of follow-up, the rates of clinical
response to treatment in group A (Tetracycline) were successful
in 6 cases (40%); versus 11 cases in group B (73.3%). Complete
Table 1 The cause(s) of malignant effusion in the two study groups.
Cause (s) of malignant eﬀusion Result (No. & %)
Grp A (n= 15) (tetracycline) Grp B (n= 15) (bleomycin)
Metastatic adenocarcinoma 5 (33.3%) 5 (33.3%)
Metastatic squamous cell carcinoma 2 (13.3%) 2 (13.3%)
Mesothelioma (epithelial) 5 (33.3%) 5 (33.3%)
Malignant myeloma 1 (6.6%) 1 (6.6%)
Lymphoma 2 (13.3%) 2 (13.3%)
Hodgkin 1 (6.6%) 1 (6.6%)
Non-Hodgkin 1 (6.6%) 1 (6.6%)
Table 2 Treatment response percentage in the two groups.
Parameter Result
Grp A
(Tetracycline)
Grp B
(Bleomycin)
Total number of patients 15 15
Clinical outcome
I. Success% 6 (40%) 11 (73.3%)
Complete response (CR)% 3 (20%) 5 (33.3%)
Partial response (PR)% 3 (20%) 6 (40%)
II. Treatment failure (TF)% 9 (60%) 4 (26.6%)
156 S. Alsayed et al.response (CR) occurred in 3 of group A cases (20%); versus 5
cases (33.3%) of group B; whereas partial response (PR)
occurred in 3 cases of group A; versus 6 cases (40%) of group
B; and treatment failure (TF) occurred in 9 of group A cases
(60%) versus 4 (26.6%) of group B cases (Tables 2 and 3).
The biochemical parameters in the pleural ﬂuid & rates
of response in the two study groups are displayed in
Table 4.
As for the mortality and the morbidity complications in the
two study groups: no mortality occurred in both groups. Mor-
bidity occurred in the form of mild-to-moderate chest pain
(lasting only for few days) in 4 of group A cases (26.6%) versus
one patient (6.6%) in group B cases. Hyperpyrexia occurred in
3 patients (20%) of group A, versus a single case (6.6%) in
group B cases. Nausea and vomiting occurred in 4 patients
of group B cases (26.6%) (Table 5).
The statistical comparison concerning the rate of response
to the pleurodesis agents used is displayed in Table 6.
Discussion
It has been estimated that up to 15% of lung cancer patients
will initially present with a MPE and that as many as 46% will
develop a pleural effusion at some point in their disease pro-
cess. In those with advanced breast cancer, effusions can be
seen in half of all patients. The most important symptom asso-
ciated with MPE is dyspnoea [17]. The traditional approach to
MPE has been to attempt obliteration of the pleural space
thereby removing the potential space where ﬂuid can accumu-
late and cause symptoms. This is achieved by introducing a
sclerosing agent to the pleural space, stimulating inﬂammation
and ﬁbrosis while maintaining apposition between the visceral
and parietal pleural surfaces. Several different sclerosing
agents have been used, most commonly talc, tetracycline,doxycycline, bleomycin and silver nitrate with talc generally
felt to be the most effective [14].
The aim of the present study was to evaluate the role of
assessing the predictive value of certain biochemical parame-
ters (present in the pleural aspirate) in assessment of the ade-
quacy and efﬁciency of two pleurodesing agents namely
Tetracyclin and Bleomycin which were injected intrapleurally
via conventional tube thoracostomy. The follow-up period in
our study was 30 days and this agreed with a study by Ruck-
deschel et al. [25] that stated that future trials should likely
assess effectiveness in 60 days rather than 90 days (done in
their study) since all reports with more than a handful of
patients, including their own comment on the extraordinary
rate of systemic progression and death in the ﬁrst month after
initiating therapy. In addition, the vast majority of ﬂuid recur-
rence is in the ﬁrst 30 days [26,27].
Tetracycline, the agent used most commonly in the past, is
no longer commercially available. At the present time, bleomy-
cin, doxycycline HCl (Vibramycin) or tetracycline HCl (Hosta-
cycline) and talc remain the agents most commonly used
[28,29]. Doxycycline has been advocated as a replacement for
tetracycline; however, recent reports suggest that up to two
thirds of patients will require multiple treatments [30]. This is
less than optimal in these patients with limited life expectancy.
Few recent trials compared doxycycline to tetracycline as a
pleurodesing agent. However, tetracycline has been compared
with bleomycin in many recent randomized trials [31]. A
statistically signiﬁcant difference was noted favoring bleomy-
cin, which was effective in 64% compared to only 33% in
the tetracycline group. Our study results conformed well to
the previous result as clinical success occurred in 11 patients
(73.3 3%) who received bleomycin, versus only 6 patients
(40%) who took tetracycline. Moreover, treatment failure
occurred more with the tetracycline group (9 patients, 60%);
versus the bleomycin group (4 patients, 26.6%) [32,33] (see
Fig. 1).
The tetracycline derivative doxycycline is an alternative
sclerosant with reported success rates of about 80%. Studies
differ regarding the inﬂuence of tumour type on the success
rate of pleurodesis. Some studies report no differences [32].
Twenty-one patients, 12 with normal pleural ﬂuid pH (7.30
or greater) and 9 with low pleural ﬂuid pH (less than 7.30)
were treated with tube thoracostomy and intrapleural tetracy-
cline for symptomatic, recurrent pleural effusions. The twenty
patients with low-pH malignant effusion had a signiﬁcantly
greater positivity on initial pleural ﬂuid cytologic examination,
a shorter mean survival and a poorer response to tetracycline
Table 3 Response of the malignant effusion to the pleurodesing agent.
Cause of malignant eﬀusion Response to the pleurodesing agent
No Grp A (n= 15) (tetracycline) Grp B (n= 15) (bleomycin)
CR PR TF CR PR TF
Metastatic adenoca 5 1 1 3 2 2 1
Metastatic Squamous cell ca 2 1 - 1 - 1 1
Mesothelioma (epithelial) 5 1 1 3 2 2 1
Malignant myeloma 1 - - 1 - 1 -
Lymphoma 2 - 1 - 1 - -
Hodgkin - - - - 1
Non-Hodgkin
I. Success = CR: Complete Response or PR: Partial response. II. Failure = TF: Treatment Failure.
Table 4 Biochemical parameters in the pleural ﬂuid & rate of response in the study groups.
Cause of malignant eﬀusion Response to the pleurodesing agent
Grp A (Tetracycline) (n= 15) Grp B (Bleomycin) (n= 15)
Result pH Glucose (mg/dl) LDH (U/L) Result pH Glucose (mg/dl) LDH (U/L)
Metastatic adenoca (5)
Patient (1) CR 7.41 113 352 CR 7.42 120 222
Patient (2) PR 7.37 90 330 CR 7.43 112 238
Patient (3) TF 7.27 48 2420 PR 7.38 68 2200
Patient (4) TF 7.29 50 2348 PR 7.32 55 2019
Patient (5) TF 7.23 49 2232 TF 7.24 45 1199
Metastatic Squamous cell ca (2)
Patient (6) CR 7.37 110 412 PR 7.37 83 320
Patient (7) TF 7.28 49 1100 TF 7.23 28 1117
Mesothelioma (epithelial) (5)
Patient (8) CR 7.43 128 180 CR 7.44 122 144
Patient (9) PR 7.32 110 390 CR 7.45 125 133
Patient (10) TF 7.22 33 1230 PR 7.29 102 760
Patient (11) TF 7.24 42 2288 PR 7.31 106 910
Patient (12) TF 7.27 50 2104 TF 7.21 51 1521
Malignant myeloma (1)
Patient (13) TF 7.23 39 2433 PR 7.34 89 236
Lymphoma (2)
Hogkin
Patient (14) PR 7.33 103 388 CR 7.45 113 134
Non-Hodgkin
Patient (15) TF 7.23 48 2100 TF 7.26 46 1498
CR: complete response, PR: partial response, TF: treatment failure.
Table 5 Morbidity and mortality complications in the study group.
Complication Result (no & % to group cases)
Grp A (n= 15) (Tetracycline) Grp B (n= 15) (Bleomycin)
*Mortality None None
*Morbidity: 7 (46.6%) 6 (40%)
Chest Pain (mild-moderate for few days) 4 (26.6%) 1 (6.6%)
Hyperpyrexia 3 (20%) 1 (6.6%)
Nausea & Vomiting – 4 (26.6%)
Seizures or Convulsions – –
No complication(s) 8 (53.3%) 9 (60%)
Malignant pleural effusion biomarkers 157pleurodesis compared with 40 patients with normal-pH
malignant effusions [23]. In our study, similar ﬁndings and
morbidity complication rate were found.Before studying the relationship between glucose and pH
levels in pleural ﬂuid and their effect on pleurodesis success
we should emphasize that according to studies primarily
Table 6 Statistical comparison of the rate of response to the pleurodesis agents used.
Clinical response Grp A (n= 15) (tetracycline) Grp B (n= 15) (bleomycin) Row totals
CR 3 5 8
Column% 20 33.30
Row% 37.5 62.50
Total% 10 16.60 26.60
PR 3 6 9
Column% 20 40
Row% 33.30 66.60
Total% 10 20 30
TF 9 4 13
Column% 60 26.60
Row% 69.20 30.70
Total% 30 13.30 43.30
Total 15 15 30
Total% 50 50 100
Clinical Success% 6/15 (40%) 11 (73.3%)
P= 0.40258 Column: Vertical arrangement of results Row: Horizontal arrangement of results.
158 S. Alsayed et al.published by the group from denver [34,22,35]. The mecha-
nisms that cause pleural ﬂuid glucose and PH to drop are
intimately related since glucose metabolism brings about intra-
pleural H+ ion generation and the cells in the pleural ﬂuid as
well as those in the lining play an active role in this metabolic
process. The abnormal pleural membrane, a result of tumour
inﬁltration and ﬁbrosis appears primarily responsible for
Low pH and glucose [36]. There is impaired glucose transfer
from blood to pleural ﬂuid and vice versa in patients with
low pH but not in normal – pH malignant effusions. Glucose
in pleural ﬂuid is metabolized into the end products CO2 and
Lactic acid at a rate similar to normal – pH MPE.
Due to abnormal pleura in patients with low pH effusions,
the rate of transport of CO2 and lactic acid out of pleural space
is slowed and accumulation occurs resulting in decreased pleu-
ral ﬂuid pH [36,37]. Rodriguez-Panadero and Mejias [40] and
Heffner et al. [43] also stated in their studies that pleural ﬂuid
glucose and pH correlate very well when the glucose level is
<60 mg/dl (P< 0.001). At higher glucose levels, there is poor
correlation (P< 0.05) (see Fig. 2).
In Group A patients in our study a signiﬁcant positive cor-
relation was found between pH and glucose levels in pleural
ﬂuid that is to say that when the glucose level increased in pleu-
ral ﬂuid the pH value also increased and when glucose levels
were low, pH values were also low. There was also a signiﬁcantTable 7 Statistical analysis differences in mean and standard devia
Variables Grp A (n= 15) (tetracycline) G
Glucose (mg/dl)
mean 62.2 7
SD 22.12 1
pH
mean 7.410 7
SD 0.1654 0
LDH (U/L)
mean 670.22 9
SD 543.21 1
* = No Statistical signiﬁcance.negative correlation between glucose levels and LDH value in
pleural ﬂuid i.e. as glucose levels increased, LDH values
decreased. This meant that the malignant inﬁltration process
of the pleura was less severe (less LDH) resulting in better
glucose transfer into the pleural cavity (more glucose in pleural
ﬂuid) and better transport of its metabolic products (CO2 and
Lactic acid) thus resulting in higher pH values of pleural ﬂuid
(Table 4). As regards Group 2 patients the same correlations
were found between glucose, LDH and pH values but were
statistically insigniﬁcant (Tables 7 and 8, see Figs. 3 and 4).
Bleomycin is the most widely used antineoplastic agent used
for pleurodesis with a success rate of 60–80%. Tetracycline,
doxycycline and talk are also recommended. A study com-
pared bleomycin with tetracycline and found that both have
similar clinical success rates, but tetracycline caused intense
pleuritic pain. [38] Jansen JP and his coworkers evaluated talk
and found similar results [39].
In our study, the success of the pleurodesis process showed
a clear relationship with glucose and pH levels in pleural ﬂuid
as in both groups and in all the observed results, more
aggressive involvement causing treatment failure (TF), was
associated with a very low pH and Glucose value and a
markedly-elevated or high LDH result; whereas clinical success
(CR, or PR) was found to occur in association with a lower
LDH, a higher glucose and pH levels (Table 4). The lowtion of biochemical parameters in pleural aspirate.
rp B (n= 15) (bleomycin) t-Value P Value
1.320* 0.1614*
6.1
3.2
0.452* 0.5358*
.44
.1431
0.689* 0.5760*
76.1
045.2
Figure 4 Mean LDH levels (U/L) between tetracycline and
bleomycin groups.
Table 8 Pearson product Moment correlation coefﬁcients ‘‘r’’ between the different biochemical parameters in the pleural aspirate.
Variable Glucose pH LDH
Grp A Grp B Grp A Grp B Grp A Grp B
Glucose (mg/dl) r= 1.000
P= -
r= 1.000
P= -
r= 0.4814
P= 0.016
r= 0.0332*
P= 0.813*
r= 0.5422*
P= 0.044*
r= 0.1372*
P= 0.054*
pH r= 0.5916*
P= 0.0332*
r= 0.9817*
P= 0.017*
r= 1.000
P= -
r= 1.000 P= - r= .7814*
P= .005*
r= .0852*
P= .916*
LDH (U/L) r= .5422*
P= .022*
r= .1372*
P= .635*
r= .6724*
P= .0741*
r= .7815*
P= .055*
r= 1.000
P= -
r= 1.000
P= -
r=Correlation coefﬁcient.
* Signiﬁcance.
Malignant pleural effusion biomarkers 159glucose level despite high pH in some patients could be
explained by the study by Rodriguez-Panadero and Mejias
[40] who found that estimated pleural ﬂuid volume had a
greater inﬂuence on glucose levels than on pH values and this
ﬁnding may be due to an increase in glucose consumption of
ﬂuid cells whether they are malignant or not [40].
A study by Nikbakhsh et al. [41] shows that pleurodesis
with bleomycin has improved the symptoms of 88% of the
patients without causing any signiﬁcant complications.
Although pleurodesis does not have any effect on patients’ sur-
vival, it has positive impact on their lives continuously by
enhancing the quality of life.
The results of our study, thus, indicate that pleurodesis
success is much more liable if pleural ﬂuid pH is >7.30
and pleural glucose levels are >60 mg/dl. Below these val-
ues, pleurodesis failure is common. Several studies reported
conforming results such as Rodriguez-Panadero and Mejias
[40] and Heffner et al. [43], who attempted pleurodesis in
62 patients having MPEs evaluated after a month. They sta-
ted that these ﬁndings were the consequence of the close
relationship found between low pleural glucose and pH lev-
els and the extension of lesions observed during follow-up
[40].In a study by Sanchez-Armengol and Rodriguez-Panadero
[42], 64 patients with MPE of different aetiology were sub-
jected to thoracoscopic pleurodesis. Out of these 5 patients
had glucose level <60 mg/dl and pH< 7.20. The results of
pleurodesis were 3 partial responses (PR) and 2 failures (F);
a success rate of 60%. 59 patients had a glucose level
>60 mg/dl and pH> 7.20. The results of pleurodesis were
46 CR, 100 PR and 3 TFs; a success rate of 94.9%. These
results are also in agreement with the results of our study.
Results from previous studies suggest that physiologic mea-
surements such as pleural ﬂuid pH and glucose levels and mor-
phologic measures of disease progression such as those
determined during thoracoscopic exploration of the pleura
are indicative of prognosis. In 1988, for example Sahn and
Good [23] demonstrated the prognostic importance of pleural
ﬂuid pH and survival in patients with malignant pleural effu-
sions. Mean survival was only 2 months if pleural ﬂuid pH
was <7.30, whereas mean survival was 10 months if pleural
ﬂuid pH was >7.30. A signiﬁcant association between both
pleural ﬂuid pH and glucose and survival was noted by Rodri-
guez and Lopez [40–43]. Patients with pleural ﬂuid pH < 7.30
had a mean survival of only 2 months, compared to 5 months
if pleural pH was >7.30 In addition, patients with pleural ﬂuid
pH < 7.30 and pleural ﬂuid glucose <60 mg/dl had a shorter
mean survival than patients with higher pH and glucose values
(1.4 months VS 5.4 months respectively).
Conclusion
The success rate of pleurodesis should be assessed in relation
to biochemical parameters such as LDH in pleural ﬂuid in
addition to pH and Glucose level as in patients with MPE,
the success of pleurodesis is usually higher when the pleural
ﬂuid pH and glucose levels are high, and the LDH level is
low. A low pH, and glucose level, and a high LDH in MPEs
have a poorer outcome of pleurodesis.
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